TBG Diagnostics Limited (TDL) is a global molecular diagnostics company dedicated to the development, manufacture and marketing of molecular diagnostics kits, instruments and services. With its research and development based in the US, Taiwan and China, TDL manufactures its products in its ISO13485 certified facilities in Xiamen, China serving the clinical labs of both hospitals and independent reference labs, blood centers and bone marrow registry labs around the world.
Texas BioGene Inc (TBG) was founded in Texas, USA
Medigen Biotechnology acquired Texas Biogene (TBG)
TBG acquired Shanghai Hao-Yuan, China
Received American Society of Histocompatability and Immunogenetics (ASHI) Accreditation
Submitted 3 in 1 Nucleic Acid testing Kits to SFDA
ID 1st AIDS blood donor in window period
Hao-Yuan acquired by Perkin Elmer for USD $38M
Ongoing global sales of HLA sub-typing kits
Nov.2014 Xiamen subsidiary established
Jan. 2015 Spin off from Medigen
TBG Diagnostics Limited listed on Australian Securities Exchange (ASX) on February 3, 2016 as TDL.